Saturday 17 October 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow TTOO
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.03 | 0.05 | 0.02 |
P/S ratio |
1.96 | 2.12 | 10.59 | 4.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.50) | (1.30) | (8.21) | (5.64) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.75 | 8.23 | 16.99 | 10.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.01) | (1.26) | (2.78) | (2.28) | |
EV/FCF |
(1.00) | (1.26) | (2.77) | (2.26) | |
Quick Ratio |
0.30 | 0.14 | 0.25 | 0.17 | |
Current Ratio |
0.45 | 0.28 | 0.60 | 0.40 | |
Net Debt/EBITDA |
1.70 | 0.50 | 0.45 | 0.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.21 | 0.25 | 0.24 | 0.25 | |
Operating CF/Net income |
0.91 | 0.86 | 1.03 | 0.62 | |
Capex/Depreciation |
(0.35) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(8.03) | (10.69) | (20.03) | (27.46) | |
Research and Development Expense of Revenue |
188.74% | 180.54% | 172.18% | 134.36% | |
Selling, General and Administrative Expense of Revenue |
312.98% | 326.93% | 280.38% | 270.93% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
43.36% | 77.39% | 10.66% | 10.88% | |
Graham Net Nets |
(2.67) | (3.09) | (0.19) | (0.57) | |
Graham Number |
68.78 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(361.83%) | 3,683.40% | 2,176.68% | 6,090.62% | |
Free Cash Flow Yield |
(342.26%) | (310.03%) | (57.92%) | (104.36%) | |
Revenue per Share |
0.64 | 0.40 | 0.14 | 0.11 | |
Operating CF per Share |
(3.61) | (2.29) | (0.66) | (0.35) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.62) | (2.29) | (0.66) | (0.35) | |
Cash per Share |
6.01 | 1.22 | 0.30 | 0.12 | |
Shareholders Equity per Share |
(10.74) | (7.41) | (0.42) | (0.65) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.74) | (7.41) | (0.42) | (0.65) | |
Free Cash Flow |
(9.44) | (11.68) | (9.24) | (6.25) | |
Working Capital |
(30.96) | (40.70) | (8.80) | (14.65) | |
Capital Expenditures |
(0.03) | — | — | — | |
Net Current Asset Value |
(37.64) | (46.97) | (14.62) | (20.01) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.79 | 1.46 | 1.32 | 1.59 | |
Average Payables |
1.41 | 2.51 | 1.96 | 2.65 | |
Average Inventory |
4.55 | 4.80 | 4.75 | 4.05 | |
Average Assets |
34.56 | 28.74 | 29.43 | 30.68 | |
Average Common Equity |
(33.85) | (43.83) | (21.16) | (15.47) |
Columns are period end dates